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Background. Wound infections after abdominal surgery are still frequent types of nosocomial infections.
Suture materials might serve as a vehicle for mechanical transport of bacteria into the surgical wound.
To prevent the contamination of suture material in surgical wounds, triclosan-coated suture materials
with antibacterial activity was developed. We here report a prospective randomized pathway controlled
trial investigating the effect of triclosan impregnation of polydioxanone sutures used for abdominal wall
closure on the rate of surgical-site infections.
Patients and methods. A total of 856 patients included in this trial underwent a standardized clinical
pathway documented abdominal wall closure after abdominal surgery. Patients were randomized to have
the fascia closed with either a 2-0 polydioxanone loop or a triclosan impregnated 2-0 polydioxanone loop.
The primary outcome was the number of wound infections. Risk factors for poor wound healing were
collected prospectively to compare the two groups.
Results. When a PDS loop suture for abdominal wall closure was used, 42 (11.3%) patients with
wound infections were detected. The number of patients with wound infections decreased significantly to
31 when the PDS plus for abdominal wall closure was used (6.4%, P < .05). Other risk factors for the
development of side infections were comparably in the two groups.
Conclusion. This clinical pathway facilitated trial shows that triclosan impregnation of a 2-0
polydioxanone closing suture can decrease wound infections in patients having a laparotomy for general
and abdominal vascular procedures. (Surgery 2013;154:589-95.)From the Departments of General and Visceral Surgery,a St€adtisches Klinikum Karlsruhe, Karlsruhe; General
and Visceral Surgery,b University of G€ottingen, G€ottingen; General, Visceral, Vascular and Paediatric Sur-
gery,c University of the Saarland, Homburg/Saar; Informatics and Biostatistics,d University of the Saarland,
Homburg/Saar, Germany; and Hirslanden Clinic St. Anna,e Lucerne, SwitzerlandSURGICAL-SITE INFECTIONS (SSIs) are among the most
common health careassociated complications.
They contribute to secondary patient morbidity
and mortality and significantly increase the cost
of care.1-3 Several patient- and care-related risk fac-
tors for SSIs have been identified in retrospectivel was funded by a restricted grant (Johnson&Johnson,
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Adequate antibiotic prophylaxis and skin scrub,4,5
the maintenance of a physiological body tempera-
ture,6,7 or oxygen supplementation8,9 were shown
to decrease SSIs in various surgical settings. Inter-
estingly, the combined application of those factors
in care bundles, however, failed to demonstrate an
effect on the overall incidence of SSIs on a na-
tional scale.10 Reasons for that failure are far
from clear but might include a low overall inci-
dence of SSIs in general surgery, inadequate sur-
veillance tools to detect SSIs, and observer
variance in the detection of surgical complications
of up to 30%.11
As early as the 1970s, surgical implants were
impregnatedwith antibacterial substances. Triclosan,SURGERY 589
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consumer products, is the latest antibacterial agent
used in coatingor impregnationof surgical sutures. It
demonstrated good bactericidal properties against
many SSI-relevant bacteria in preclinical studies12
and decreased wound infections in several random-
ized trials.13,14 Other studies failed to demonstrate a
protective effect either due to under powering of
the trial15 or due to a lack of control of confounding
factors of wound infections.16
Clinical pathways have been developed to stan-
dardize medical and surgical diagnosis and treat-
ment.When applied as a strategic care tool and used
ina consistentmanner, they are able to incrementally
improve outcome in patients receiving advanced
carelike cardiac surgery.17 Furthermore, we and
others have demonstrated that electronic documen-
tation of the various steps of clinical pathways and
controlled alteration of a singular step within a path-
way allow for large-scale clinical studies at minimal
costs.18-20 We here report a prospective randomized
pathway controlled trial (NCT00998907) in which
we investigated the effect of impregnating, with tri-
closanim, polydioxanone sutures used for abdomi-
nal wall closure on the rate of SSIs.
PATIENTS AND METHODS
This prospective, double-blind randomized trial
was approved by the local ethical committee and
was registered as a clinical trial as NCT00998907.
Starting in September 2009, all patients scheduled
to undergo a laparotomy were screened for this
trial. After giving written informed consent, all
patients included in the trial underwent a stan-
dardized clinical pathway documented abdominal
wall closure after abdominal surgery.
Patients were randomized in blocks of 50 to 100
patients to have the fascia closed with either a 2-0
polydioxanone loop (PDS II, 150 cm; Ethicon
GmbH, Norderstedt, Germany) or a triclosan im-
pregnated 2-0 polydioxanone loop (PDS Plus, 150
cm; Ethicon GmbH). Surgeons, patients, as well as
wound monitors were blinded towards the use of
either PDS II or PDS Plus. PDS II and PDS Plus
sutures cannot be distinguished from each other
in terms of physical properties such as color, feel of
the suture, or tying properties. The primary end
point was an SSI at the laparotomy incision during
the hospital stay and follow-up within 2 weeks after
discharge from the hospital.
Patients with previous methicillin-resistant
Staphylococcus aureus contamination or patients at
risk for methicillin-resistant Staphylococcus aureus
contamination were screened preoperatively and
decontaminated, if elective procedures wereplanned.21 All patients undergoing colorectal re-
sections had a preoperative bowel preparation
with 3 L of prepacol (Prepacol; Guerbert GmbH,
Sulzbach/Taunus, Germany). All patients had a
regular shower without iodine within 24 hours
before surgery followed by an abdominal wall
hair removal.22 All patients received antibiotic pro-
phylaxis (standard antibiotics: metronidazole and
ceftriaxone; metronicazole and clindmycin in
case of allergy) within 60 minutes before the skin
incision.23
After skin disinfection with a polyvidon-iodine,
propran-1-ol solution (Braunoderm, B. Braun, Mel-
sungen, Germany), the skin was incised with a
scalpel. Subcutaneous tissue, the fascia, and perito-
neum were dissected with an electric knife. A skin
drape24 was used in all patients, and wound edges
were protected with surgical swaps. In patients
with a contaminated abdominal cavity, those swaps
were soaked in diluted polyvidone iodine solution.
Patients having procedures lasting longer than 4
hours received a second dose of antibiotics.23 Tem-
perature was kept above 358C in all patients with a
warming device (Warm-Touch; Mallinckrodt Medi-
cal, Hennef/Sieg, Germany). Patients with an organ
space infection upon laparotomy underwent an ab-
dominal lavage with Ringer’s lactate solution of at
least 5 L, as described previously.25,26
The abdominal wall was closed with a continu-
ous suture, with a suture/wound length ratio of
4:1, with a stitch length of approximately 1 cm,
taking the fascia at approximately 1.5 cm distance
from the midline incision.27 The peritoneum was
not closed separately. After the fascia was closed,
the wound was rinsed with Ringer’s lactate solution
to clean out blood and cell debris. No subcutane-
ous sutures were used. The skin was closed with sta-
ples (Appose Single-Use Skin Stapler; Covidien,
Mansfield, MA), and subsequently disinfected
with polyvidone iodine in alcohol. Finally a sterile
drape was applied to the wound and was left in
place for at least 24 hours unless macroscopic
bleeding soiled the drape. In patients with a his-
tory of cardiovascular disease, oxygen was supplied
via a nasal tube to maintain an oxygen saturation
of >95% postoperatively.9 Patients requiring inten-
sive care treatment had a tight postoperative glu-
cose control and correction of hyperglycemic
states by continuous or intermittent insulin
administration.
Postoperatively wounds were assessed daily at
the bedside by two observers blinded to the use of
triclosan following a standard protocol included in
the care pathway (see Supplementary data online).
The definition of SSIs followed Centers for Disase
1497 consecutive patients screened 
1042 patients consented and included 
32 patients refused surgery 
43 had non-open therapy 
967 patients operated per protocol 
559 PDS PLUS, 408 PDS II 
12 patients abdomen not closed 
18 early burst abdomen 
71 revisions 
10 patients died
856 patients were evaluated 
Fig. Flow chart of screened and treated patients of the
NCT00998907 trial.
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tion was identified by the presence of erythema,
induration, pain, and discharge of serous or con-
taminated fluid. Therefore, a bedside assessment
was chosen as opposed to an assessment of wound
pictures by remote investigators.29 Wounds were as-
sessed during the hospital stay and during follow-
up 2 weeks postoperatively.
In patients with clinical signs for wound infec-
tions, bacterial cultures were obtained. In patients
having secondary incisions (additional chemother-
apy port for instance), only the primary, ie, ab-
dominal incision was evaluated.
All data were entered via an electronic report
form into our prospective clinical pathway data
system (Clinical pathway module by GSD, ISH-
Med, SAP Platform; SAP, Walldorf Germany30,31).
On the basis of our previous results, we assumed
an SSI reduction from 12% to 6%. Therefore, a
sample size of 350 patients for each arm was calcu-
lated to achieve a power of 1  b = 0.80 for the
one-sided v2 test at level a = 0.025 and a low
drop-out rate of 5%.
Differences betweengroupswere calculatedby v2
or Fisher exact test for categorical variables, Mann-
Whitney U test for continuously variables, using
the SPSS (Version 14, Chicago, IL) software, and
SAS Analytics (SAS Institute GmbH; Heidelberg,
Germany).Data included all biographic and periop-
erative data as well as postoperative outcome. Amul-
tiple logistic regression analysis was performed
entering the risk factors gender, American Society
of Anesthesiologists classification, body mass index
>30, malignant disease, the wound status, and anti-
septic coating as variables. Data are given as absolute
numbers, mean and SEM or as median (range) un-
less indicated otherwise.
RESULTS
Between September 2009 and September 2011,
1,497 consecutive patients admitted to our depart-
ment were screened to undergo open abdominal
exploration and surgery and closure of the incision
in a standardized fashion (Fig).27 A total of 1,042
of those patients gave written consent and were
included in the trial.
Thirty-two patients subsequently refused sur-
gery, and 43 patients had minimally invasive pro-
cedures or received nonsurgical therapies. Of the
967 patients undergoing open abdominal surgery
and closure with a polydioxanone suture, 18
patients had a burst abdomen, and 71 patients
had a planned revision within 30 days or an on
demand re-laparotomy for organ space infections.
Those patients were excluded from further analysisbecause a secondary contamination of the wound
and subsequent wound infection might be unre-
lated to the use of triclosan impregnated sutures
during the first procedure. Ten patients died
postoperatively, and in 12 patients the abdomen
was not closed during the initial procedure, leav-
ing 856 patients for complete evaluation of their
wound status.
A total of 371 patients were randomized to PDS
II and 485 patients to PDS II Plus. Sex, age, and
BMI as well as the ASA classification was not
different between the two groups. There were
more clean wounds in the PDS II group and
more clean-contaminated wounds in the PDS
Plus groups (Table I), the difference, however,
was not significant. Blood loss, duration of surgery,
and duration of hospital stay were comparable be-
tween the two groups as was the duration of sur-
gery (Table II). The rate of wound infection was
11.3% in the PDS II group and 6.4% in the PDS
Plus group (P < .05).
On multivariate analysis, the use of a PDS Plus
suture decreased the odds of developing a wound
infection in abdominal surgery to 0.501 (95%
confidence interval 0.3–0.9, P < .05). Patients
who underwent colorectal resections (ie, clean
contaminated or contaminated procedures) had
a 3.3-fold greater odds of developing a wound
infection compared with patients undergoing non-
colorectal procedures. Patients with a body mass
index of 30 kg/m2 or more had a 1.68-fold risk
of developing a wound infection (95% confidence
interval 0.8-3.2, P = .12; Table III).
Table I. Demographic data of cohort
Parameter PDS II, n = 371 PDS Plus, n = 485 P value
Sex, n (%) .616
Male 224 (60.4) 301 (62.1)
Female 147 (39.6) 184 (37.9)
Age, years 63 ± 13 63 ± 13 .923
BMI, n (%) .713
<18 7 (1.9) 14 (2.9)
18–25 181 (48.8) 221 (45.6)
26–30 129 (34.8) 174 (35.9)
>30 54 (15.8) 76 (16.4)
ASA, n (%) .550
1 21 (7.3) 25 (5.5)
2 164 (56.9) 249 (54.4)
3 98 (34) 176 (38.4)
4 5 (1.7) 8 (1.7)
Inflammatory bowel disease, n (%) 7 (1.9) 14 (2.9) .869
Diabetes mellitus, n (%) 35 (9.4) 49 (10.1) .419
Blood transfusion, n (%)* 14 (3.9) 23 (4.8) .369
Malignancy, n (%) 264 (71.4) 355 (73.2) .550
Wound classification, n (%) <.05
Clean 245 (66) {22; 8.9%}y 286 (59) {14; 4.8%}y
Clean contaminated 97 (26.1) {16; 16.5%}y 162 (33.4) {14; 8.6%}y
Contaminated 25 (6.7) {4; 16%}y 37 (7.6) {3; 8.1%}y
Septic 4 (1.1) {0}y 0 (0) {0}y
*Number of patients with perioperative blood transfusion.
yBrackets indicate the number of infections within each classification.
ASA, American Society of Anesthesiologists; BMI, body mass index.
Table II. Peri- and postoperative data of cohort
Parameter PDS II, n = 371 PDS Plus, n = 485 P value
Blood loss, mL 366 ± 509 316 ± 485 .176
IHOS, days 15 ± 13 (2134) 11 ± 18 (2209) .300
OR time, min 137 ± 68 138 ± 65 .860
Access, n (%) .218
Median laparotomy 279 (75.2) 382 (78.8)
Transverse laparotomy 92 (24.8) 103 (21.2)
Type of surgery, n (%) .883
Upper GI tract 41 (11.1) {2; 5%}* 59 (12.2) {3; 5%}*
Hepatopancreatobiliary 173 (46.6) {14; 8%}* 210 (43.4) {9; 4%}*
Small intestine 14 (3.8) {3; 21%}* 19 (3.9) {1; 5%}*
Colorectal 100 (27.7) {19; 19%}* 143 (29.5) {17; 12%}*
Vascular surgery 24 (6.5) {0}* 26 (5.4) {0}*
Other 19 (5.1) {4; 21%}* 27 (5.4) {1; 4%}*
Wound infection 42 (11.3) 31 (6.4) <.05
*Brackets indicate the number of infections within each category.
GI, Gastrointestinal; IHOS, in hospital stay; OR, operating room.
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were recorded in all patients. In patients develop-
ing wound infections, swelling and pain were the
first signs seen on the 2nd and 3rd postoperative
days. Erythema and warmth were later signs of
wound infections, following on the 7th and 10th
day, postoperatively (Fig). The proportion of bac-
terial species found in infected wounds is shownin Table IV. No difference could be detected
between the two groups (P > .05). Most patients
developing SSI were treated conservatively (PDS
II: 35/42 [83.3%]; PDS Plus: 22/31 [71.0%]);
five patients in the PDS II group and eight patients
in the PDS Plus group had major surgical wound
revisions (PDS II: 5/42 [11.9%]; PDS Plus: 8/31
[25.8%]).
Table III. Regression analysis
Parameter No wound infection Wound infection Odds ratio (95% CI) P value
PDS Plus suture 454 31 0.501 (0.30.9) <.05
Female sex 303 28 1.08 (0.61.9) .78
BMI > 30 116 14 1.68 (0.83.2) .12
ASA > 2 262 25 1.14 (0.61.9) .63
Diabetes mellitus 76 9 1.21 (0.52.8) .66
Wound status contaminated or septic 59 7 1.05 (0.42.6) .71
Malignancy 563 56 1.1 (0.62.0) .75
Colorectal procedure 207 36 3.3 (1.95.7) <.05
ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval.
Table IV. Proportion of bacterial scpecies found in
infected wounds
PDS II PDS Plus
SSI 11.3% (42/371) 6.4% (31/485)
Bacterial species
Staphylococci 23.1% 23.1%
Enterococci 23.1% 30.1%
Streptococci 5.1% 5.1%
Pseudomonas spp. 0 5.1%
Enterobacteriacae 5.1% 2.5%
Others 15.4% 23.1%
SSI, Surgical-site infection.
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In this prospective patient-, surgeon-, and
observer-blinded randomized trial, we found a de-
crease in the rate of SSIs in patients undergoing
fascia closure after a laparotomy with a triclosan-
impregnated polydioxanone suture of 43% com-
pared with a fascia closure with an unimpregnated
polydioxanone suture. SSIs are the second most
frequent health care associated complications,
amounting to approximately 300,000 infections per
year in the United States alone.32 Depending on the
type of surgery the incidence was reported to range
between 0% and >25%1-3 in patients with contami-
nated surgical sites. Clearly, comorbidities such as di-
abetes, obesity, malignancy, and cachexia1,2 increase
the risk for SSIs; however, they might not be correct-
able preoperatively in patients requiring immediate
surgery. On the other hand, health careassociated
risk factors like inadequate skin preparation and an-
tibiotic prophylaxis,4,5 surgical technique and long
operating times,33 as well as inadequate periopera-
tive care are amenable to correction. Interestingly,
several surveillance studies found compliance rates
with current antibiotic prophylaxis guidelines for
instance tobe 35%or less.34,35 Also, under study con-
ditions, following stringent intraoperative hygiene
protocols may not be greater than 65%36 without
previous and continuous education and training.Reasons for that low compliance are not merely
neglect but are often caused by a lack of standard-
ization and training, personal fluctuation, time
and resource constraints, as well as insufficient
communication between care providers.37 Those
factors, together with the multi factorial etiology
of SSIs and a lack of standardized methods for
SSI surveillance,28 might be some of the reasons
for the failure of large scale programs to reduce
SSIs.38
Additionally, those factors might complicate the
design but also interpretation of clinical especially
multicenter trials that try to translate a well proven
biological effect of a singular intervention or
molecules into clinical practice. Triclosan, for
instance, a chlorinated phenolic molecule, was
shown to have profound antibacterial activities
against a number of gram-positive and gram-
negative bacteria, with a 90% to 99.9% reduction
in Escherichia coli and Staphylococcus aureus inoccu-
lates, respectively.39 In vivo it reduces bacterial
adhesion to braided sutures, thus decreasing
microbial viability in surgical wounds.40 The anti-
bacterial activity of triclosan-impregnated sutures
was maintained until the sutures dissolved.39
Subsequent clinical studies were able to demon-
strate the beneficial effect of triclosan on SSIs in
randomized13,14 aswell as large-scale, well-controlled
retrospective studies.18,19 Other trials, however,
failed to demonstrate an effect of triclosan impreg-
nated sutures on SSIs probably because of under-
powering of the trials in patients at low risk for
SSIs.15,41 Other studies lacked an adequate control
of confounding factors for clinical signs of SSIs like
limb ischemia42,43 or they failed to standardize peri-
operative management and wound surveillance.16
One of the limitations of our previous two trials
was the lack of randomization, which was corrected
in the present study. For logistic reasons and to
facilitate a high patient recruitment rate, random-
ization was facilitated in a group fashion rather
than a randomization of each individual, assigning
Surgery
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control or the triclosan treatment group. This
allowed for a very high recruitment rate, large
study groups with little variation in perioperative
management and surgical technique, and con-
stancy in the staff involved in patient care. Also,
the computer-based clinical pathway system ap-
plied as a strategic management tool provided a
high grade of documentation and standardization.
That high recruitment rate of more than 850
patients within 1 year in a single institution
guaranteed not only a high constancy of treatment
but allowed a rapid clinical assessment of new
surgical and medical products, which sharply con-
trasts to conventional recruitment rates of less than
50 patients/year and study recruitment times of
several years29 for similar trials conducted at other
high-volume centers.11,43 In addition to those ad-
vantages, the current clinical pathway facilitated
study design is significantly less expensive than
conventional multicenter RCT.
The high documentation density and quality of
the surgical site in this study allows for the first
time to delineate a time course of SSIs after
laparotomy. Wound secretion and pain were early
signs occurring as early as 2 to 3 days postopera-
tively, followed by redness and heat later in the
course of SSIs. To develop early intervention strat-
egies for abdominal SSIs, that finding would need
to be confirmed in further studies.
In summary, this clinical pathway facilitated trial
confirmed previous studies of our group that
triclosan impregnation of a 2-0 polidioxanone
closing suture decreases wound infections in pa-
tients having a laparotomy for general and abdom-
inal vascular procedures.
Furthermore, the use ofclinical pathways and
altering a single parameter within this pathway in a
blinded randomized fashion might be a novel tech-
nique for clinical studies. Those studies can rapidly
assess novel medical products at a fraction of the
cost of conventional multicenter clinical trials.
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